companydata.dkcompanydata.dk

Daiichi Sankyo Nordics ApS: Financial statements 2023

CVR: 39371049

Source: annual report 2023, Danish Business Authority

01/04/2022 – 31/03/2023

Daiichi Sankyo Nordics ApS (CVR 39371049) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 47,832,587 and a net result of DKK 2,350,138 compared with DKK 46,355 the year before. That is an increase of 34.3% compared with the year before. Equity in the 2023 report amounted to DKK 5,733,435. The solvency ratio was 5.4%. The company had 24 employees in the financial year.

Gross Profit
DKK 47,832,587
Profit/Loss
DKK 2,350,138
Equity
DKK 5,733,435
Total Assets
DKK 106,679,898
Employees
24

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023-47.8M2.4M5.7M24
2022-35.6M46K3.4M22
2021-27.4M846K3.3M16
2020-20.6M1.2M2.5M16
2019-2.9M253K1.3M2

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Jacob Wessel-Tolvig joins the board of Daiichi Sankyo Nordics ApSJan 19, 2023

As of January 19, 2023, Jacob Wessel-Tolvig has joined the board of directors of Daiichi Sankyo Nordics ApS.

Stefan Gerd Koch leaves the board of Daiichi Sankyo Nordics ApSJan 19, 2023

As of January 19, 2023, Stefan Gerd Koch has left the board of directors of Daiichi Sankyo Nordics ApS.

About Daiichi Sankyo Nordics ApS

Daiichi Sankyo Nordics ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Daiichi Sankyo Oncology Nordics ApS. The management consists of Christophe Tiberghien. The board consists of Christophe Tiberghien, Jacob Wessel-Tolvig and Karin Margaretha Heisterberg. The company is owned by Daiichi Sankyo Oncology Europe GmbH. The company has 32 employees (2026). In 2026, the company reported a gross profit of DKK 83,558,930 and a net result of DKK 17,269,490 compared with DKK 9,020,707 the year before. Equity in the 2026 report amounted to DKK 40,346,412.

Source: annual report 2026, Danish Business Authority

Other financial years